Compare PASG & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PASG | TPST |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 30.9M |
| IPO Year | 2020 | 2012 |
| Metric | PASG | TPST |
|---|---|---|
| Price | $5.90 | $1.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $14.00 | $11.00 |
| AVG Volume (30 Days) | 109.2K | ★ 306.0K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $1.50 |
| 52 Week High | $20.00 | $12.22 |
| Indicator | PASG | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 44.57 |
| Support Level | N/A | $1.50 |
| Resistance Level | $8.65 | $2.48 |
| Average True Range (ATR) | 1.33 | 0.22 |
| MACD | -0.46 | 0.02 |
| Stochastic Oscillator | 2.54 | 30.53 |
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.